Is PAVmed Inc. (PAVM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 331.9% / 30% | 12.3% / 30% | 0.2% / 30% | 8.48% / 5% | ✗ NOT HALAL |
| DJIM | 331.9% / 33% | 12.3% / 33% | 0.2% / 33% | 8.48% / 5% | ✗ NOT HALAL |
| MSCI | 103.9% / 33% | 3.9% / 33% | 0.1% / 33% | 8.48% / 5% | ✗ NOT HALAL |
| S&P | 331.9% / 33% | 12.3% / 33% | 0.2% / 33% | 8.48% / 5% | ✗ NOT HALAL |
| FTSE | 103.9% / 33% | 3.9% / 33% | 0.1% / 50% | 8.48% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -96880.0% | |
| Net Margin | 10672.4% | |
| Return on Equity (ROE) | 17.4% | |
| Return on Assets (ROA) | -36.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$34M |
| Free Cash Flow | -$34M |
| Total Debt | $32M |
| Debt-to-Equity | 36.0 |
| Current Ratio | 0.4 |
| Total Assets | $31M |
Price & Trading
| Last Close | $8.94 |
| 50-Day MA | $9.76 |
| 200-Day MA | $12.41 |
| Avg Volume | 1.1M |
| Beta | 0.9 |
|
52-Week Range
$6.00
| |
About PAVmed Inc. (PAVM)
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PAVmed Inc. (PAVM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PAVmed Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PAVmed Inc.'s debt ratio?
PAVmed Inc.'s debt ratio is 331.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 103.9%.
What are PAVmed Inc.'s key financial metrics?
PAVmed Inc. has a market capitalization of $8M, and revenue of $3M. Return on equity stands at 17.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.